Lynette J Menezes1, Ubin Pokharel2, Staci L Sudenga2, Matthys H Botha3, Michele Zeier4, Martha E Abrahamsen2, Richard H Glashoff5, Susan Engelbrecht5, Maarten F Schim van der Loeff6, Louvina E van der Laan3, Siegfried Kipping3, Douglas Taylor7, Anna R Giuliano2. 1. Division of Infectious Disease and International Medicine, University of South Florida, Tampa, Florida, USA. 2. Center for Infection Research in Cancer, Moffitt Cancer Center, Tampa, Florida, USA. 3. Department of Obstetrics and Gynaecology and Unit for Gynaecological Oncology, Tygerberg Hospital, Stellenbosch University, Cape Town, South Africa. 4. Department of Medicine and Centre for Infectious Diseases, Stellenbosch University, Cape Town, South Africa. 5. Division of Medical Virology, Stellenbosch University and NHLS Tygerberg, Cape Town, South Africa. 6. Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands. 7. FHI 360, Durham, North Carolina, USA.
Abstract
OBJECTIVE: To estimate the prevalence and describe the patterns of concurrent human papillomavirus (HPV) and STIs and associated factors among HIV-negative young Western Cape, South African women participating in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) trial. METHODS:HIV-negative women aged 16-24 years old were enrolled in the EVRI trial (NCT01489527) and randomised to receive the licensed four-valent HPV vaccine or placebo. At study entry, participants were clinically evaluated for five STIs: herpes simplex virus type 2 (HSV-2), chlamydia, gonorrhoea, syphilis and disease-causing HPV genotypes (6/11/16/18/31/33/35/39/45/51/52/56/58/59/68). Demographic and sexual history characteristics were compared among women with STI co-infections, single infection and no infection using Pearson χ2 and Mann-Whitney tests. ORs were calculated to evaluate factors associated with STI co-infection prevalence. RESULTS: Among 388 young women, STI co-infection prevalence was high: 47% had ≥2 concurrent STIs, 36% had a single STI and 17% had none of the five evaluated STIs. HPV/HSV-2 (26%) was the most prevalent co-infection detected followed by HPV/HSV-2/Chlamydia trachomatis (CT) (17%) and HPV/CT (15%). Co-infection prevalence was independently associated with alcohol use (adjusted OR=2.01, 95% CI 1.00 to 4.06) and having a sexual partner with an STI (adjusted OR=6.96, 95% CI 1.53 to 30.08). CONCLUSIONS: Among high-risk young women from underserved communities such as in Southern Africa, a multicomponent prevention strategy that integrates medical and behavioural interventions targeting both men and women is essential to prevent acquisition of concurrent STI infections and consequent disease. TRIAL REGISTRATION NUMBER: NCT01489527; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
RCT Entities:
OBJECTIVE: To estimate the prevalence and describe the patterns of concurrent human papillomavirus (HPV) and STIs and associated factors among HIV-negative young Western Cape, South African women participating in the Efficacy of HPV Vaccine to Reduce HIV Infection (EVRI) trial. METHODS: HIV-negative women aged 16-24 years old were enrolled in the EVRI trial (NCT01489527) and randomised to receive the licensed four-valent HPV vaccine or placebo. At study entry, participants were clinically evaluated for five STIs: herpes simplex virus type 2 (HSV-2), chlamydia, gonorrhoea, syphilis and disease-causing HPV genotypes (6/11/16/18/31/33/35/39/45/51/52/56/58/59/68). Demographic and sexual history characteristics were compared among women with STI co-infections, single infection and no infection using Pearson χ2 and Mann-Whitney tests. ORs were calculated to evaluate factors associated with STI co-infection prevalence. RESULTS: Among 388 young women, STI co-infection prevalence was high: 47% had ≥2 concurrent STIs, 36% had a single STI and 17% had none of the five evaluated STIs. HPV/HSV-2 (26%) was the most prevalent co-infection detected followed by HPV/HSV-2/Chlamydia trachomatis (CT) (17%) and HPV/CT (15%). Co-infection prevalence was independently associated with alcohol use (adjusted OR=2.01, 95% CI 1.00 to 4.06) and having a sexual partner with an STI (adjusted OR=6.96, 95% CI 1.53 to 30.08). CONCLUSIONS: Among high-risk young women from underserved communities such as in Southern Africa, a multicomponent prevention strategy that integrates medical and behavioural interventions targeting both men and women is essential to prevent acquisition of concurrent STI infections and consequent disease. TRIAL REGISTRATION NUMBER: NCT01489527; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Jennifer S Smith; Rolando Herrero; Cristina Bosetti; Nubia Muñoz; F Xavier Bosch; José Eluf-Neto; Xavier Castellsagué; Chris J L M Meijer; Adriaan J C Van den Brule; Silvia Franceschi; Rhoda Ashley Journal: J Natl Cancer Inst Date: 2002-11-06 Impact factor: 13.506
Authors: V W Halling; M F Jones; J E Bestrom; A D Wold; J E Rosenblatt; T F Smith; F R Cockerill Journal: J Clin Microbiol Date: 1999-10 Impact factor: 5.948
Authors: L A Koutsky; K K Holmes; C W Critchlow; C E Stevens; J Paavonen; A M Beckmann; T A DeRouen; D A Galloway; D Vernon; N B Kiviat Journal: N Engl J Med Date: 1992-10-29 Impact factor: 91.245
Authors: Esther E Freeman; Helen A Weiss; Judith R Glynn; Pamela L Cross; James A Whitworth; Richard J Hayes Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Ongeziwe Taku; Harris Onywera; Zizipho Z A Mbulawa; Charles B Businge; Tracy L Meiring; Anna-Lise Williamson Journal: Microbiol Spectr Date: 2022-06-01
Authors: Anastasiya Muntyanu; Vladimir Nechaev; Elena Pastukhova; James Logan; Elham Rahme; Elena Netchiporouk; Andrei Zubarev; Ivan V Litvinov Journal: Lancet Reg Health Eur Date: 2022-06-30
Authors: Andrew Medina-Marino; Susan Cleary; Christina A Muzny; Christopher Taylor; Ashutosh Tamhane; Phuti Ngwepe; Charl Bezuidenhout; Shelley N Facente; Koleka Mlisana; Remco P H Peters; Jeffrey D Klausner Journal: Trials Date: 2022-05-24 Impact factor: 2.728
Authors: Zizipho Z A Mbulawa; Cari van Schalkwyk; Nai-Chung Hu; Tracy L Meiring; Shaun Barnabas; Smritee Dabee; Heather Jaspan; Jean-Mari Kriek; Shameem Z Jaumdally; Etienne Muller; Linda-Gail Bekker; David A Lewis; Janan Dietrich; Glenda Gray; Jo-Ann S Passmore; Anna-Lise Williamson Journal: PLoS One Date: 2018-01-02 Impact factor: 3.240
Authors: Ana Paula Almeida Cunha; Ilka Kassandra Pereira Belfort; Francisco Pedro Belfort Mendes; Gerusinete Rodrigues Bastos Dos Santos; Lucas Henrique de Lima Costa; Pablo de Matos Monteiro; Renata Lemos Gaspar; Mariele Borges Ferreira; Alice de Sá Ferreira; Sally Cristina Moutinho Monteiro; Flávia Castello Branco Vidal Journal: Interdiscip Perspect Infect Dis Date: 2020-10-29
Authors: Sarah Connolly; Kristin M Wall; Rachel Parker; William Kilembe; Mubiana Inambao; Ana-Maria Visoiu; Tyronza Sharkey; Eric Hunter; Susan Allen Journal: Int J STD AIDS Date: 2020-03 Impact factor: 1.359
Authors: Gui Liu; Nelly R Mugo; Elizabeth R Brown; Nyaradzo M Mgodi; Zvavahera M Chirenje; Jeanne M Marrazzo; Rachel L Winer; Leila Mansoor; Thesla Palanee-Phillips; Samantha S Siva; Logashvari Naidoo; Nitesha Jeenarain; Zakir Gaffoor; Gonasagrie L Nair; Pearl Selepe; Clemensia Nakabiito; Baningi Mkhize; Brenda Gati Mirembe; Marthinette Taljaard; Ravindre Panchia; Jared M Baeten; Jennifer E Balkus; Florian Hladik; Connie L Celum; Ruanne V Barnabas Journal: AIDS Date: 2022-02-01 Impact factor: 4.632